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Human Papilloma viruses and Breast 
Cancer – Assessment of Causality
James Sutherland Lawson*, Wendy K. Glenn and Noel James Whitaker
School of BABS, University of New South Wales, Sydney, NSW, Australia
High risk human papilloma viruses (HPVs) may have a causal role in some breast can-
cers. Case–control studies, conducted in many different countries, consistently indicate 
that HPVs are more frequently present in breast cancers as compared to benign breast 
and normal breast controls (odds ratio 4.02). The assessment of causality of HPVs in 
breast cancer is difficult because (i) the HPV viral load is extremely low, (ii) HPV infections 
are common but HPV associated breast cancers are uncommon, and (iii) HPV infections 
may precede the development of breast and other cancers by years or even decades. 
Further, HPV oncogenesis can be indirect. Despite these difficulties, the emergence of 
new evidence has made the assessment of HPV causality, in breast cancer, a practical 
proposition. With one exception, the evidence meets all the conventional criteria for a 
causal role of HPVs in breast cancer. The exception is “specificity.” HPVs are ubiquitous, 
which is the exact opposite of specificity. An additional reservation is that the prevalence 
of breast cancer is not increased in immunocompromised patients as is the case with 
respect to HPV-associated cervical cancer. This indicates that HPVs may have an indi-
rect causal influence in breast cancer. Based on the overall evidence, high-risk HPVs 
may have a causal role in some breast cancers.
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inTRODUCTiOn
High-risk human papilloma viruses (HPVs) may have a causal role in some breast cancers. However, 
the assessment of causality of HPVs in breast cancer is extremely difficult. The main difficulty is 
that HPV infections are common, but HPV-associated breast cancers are uncommon. Further, 
HPV infections may precede the development of breast and other cancers by years or even decades. 
Further, HPV oncogenesis can be indirect. Despite these difficulties, the emergence of new evidence 
has made this assessment a practical proposition.
A good starting point is to review the evidence according to the criteria developed by A. Bradford 
Hill in 1965 and later modified by others (1–3). The Hill criteria are (i) strength of the association, (ii) 
consistency, (iii) specificity, (iv) temporality (time sequence), (v) biological gradient, (vi) plausibility, 
(vii) coherence, (viii) experimental evidence, and (ix) analogy. There is an overlap between several 
criteria such as strength of the association and specificity. If viruses, such as high risk for cancer 
HPVs, fulfill all or most of these criteria, there is a likely relationship, but not necessarily a conclusive 
confirmation of causality. One weakness of the Hill criteria is that each is given similar weight or 
importance. This is in contrast to the key requirement of zur Hausen that there should be a regular 
presence of the nucleic acid of the virus in specific malignant tumors (3). Even this criteria may 
FiGURe 1 | (A) HPV identified by in situ PCR in breast ductal carcinoma 
in situ. Koilocytes are present in this specimen. (B,C) HPV E7 protein in a 
benign breast specimen (B). No HPV E7 protein in invasive breast cancer 
4 years later in the same patient (C).
TABLe 1 | HPv viral loads in HeLa (cervical cancer cell line), breast 
cancer tissues, and cervical cancer tissues (4, 5).
HeLa cells Breast cancer Cervical cancer
HPV gene copy/cell 10–50 0.00054–0.0021 13
HPV gene copy/ng 1,510–7,558 0.082–0.32 2,000
HPV gene copy/50 ng 75,500–377,000 4–16 98,500
The viral load is approximately 2,000-fold greater in cervical cancer as compared to 
breast cancer.
ng = nanogram.
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be difficult because of the ability of HPVs to act indirectly by 
causing genetic instability or promoting the influence of other 
viruses such as Epstein Barr virus (EBV).
Strength of the Association between 
identification of HPv and Breast Cancer
The HPV viral load in breast cancer is extremely low as compared 
to HPV in cervical cancer (approximately 2,000-fold lower, see 
Table 1) (4, 5). As a consequence, identification of HPV in breast 
tumors is difficult whether by amplification techniques such as 
polymerase chain reaction (PCR) or massive parallel sequencing. 
The low viral load is the likely reason that several laboratories 
have not been able to detect HPV. On the other hand, HPV gene 
sequences have been identified in breast tumors in over 40 studies 
conducted in 20 countries (6, 7).
The prevalence of high-risk HPV positive breast cancers varies 
between 0 and 2% in some Chinese Provinces to 86% in North 
America (7). HPV types 16 and 18 are the most prevalent, but 
HPV 33 and 58 are common in China and Japan (8, 9). A recent 
meta-analysis of 22 case–control studies indicated that HPV 
infection was associated with an increased risk of breast cancer 
as compared to benign or normal breast controls (odds ratio 4.02) 
(7). Increased risk of breast cancer is influenced by geographic 
region, PCR techniques, and publication period. All of these 
studies were based on PCR analyses. HPV gene sequences identi-
fied by in situ PCR are shown in Figure 1. High risk HPVs have 
been identified in invasive breast cancers using Next Generation 
Sequencing (NGS), but this technique is much less sensitive than 
PCR (10).
Case–control studies, which compare the prevalence of 
high-risk HPVs in breast cancer as compared to benign breast 
or normal breast are shown in Table 2. The prevalence of HPV 
is fourfold higher in breast cancer (21.5%) than controls (5.1%) 
in studies conducted in different laboratories in a wide range of 
countries. This parallels the findings of a recent meta-analysis 
based on selected studies, which are included in this Table (7). 
It is of interest that high-risk HPVs were identified in only 4.1% 
of benign or normal (usually from cosmetic surgery) as com-
pared to 17.7% in non-cancerous breast tissues located next to 
breast cancer tissues. The implication is that HPVs may be have 
increased prevalence in non-cancerous breast tissues located next 
to cancerous breast tissues and should not be used as controls.
In a recent study, it has been shown that women with HPV-
associated cervical pathology are at increased risk from the same 
HPV type positive breast cancer (31). This observation confirms 
large epidemiological studies, which show that women with squa-
mous or glandular precancer of the cervix have a significantly 
higher risk of subsequent breast cancer than the general female 
population – odds ratios 1.10 and 1.52, respectively (32, 33).
Consistency
The HPV viral load in breast cancer is extremely low (see 
Table 1). Accordingly, the identification of HPVs by both PCR 
and NGS is difficult. This may explain the very different findings 
from the 10 case–control studies conducted in various locations 
in China. The identification of HPVs in China vary from 0 to 
60%. Similarly, the findings in Iran vary from 0 to 34%. There are 
three relevant studies based on NGS – Tang et al., Khoury et al., 
and Lawson et al. (10, 34, 35). High risk HPVs were not identified 
in breast cancers from the The Cancer Genome Atlas (TCGA) 
series of approximately 800 breast cancers in either the Tang or 
Khoury studies but were identified in 2.3% of the same series by 
Lawson et al. (10, 34, 35). Clearly, PCR-based analyses are much 
more sensitive than current NGS-based analyses. The reasons for 
this discrepancy have been considered by Vinner et al. who has 
shown that NGS-based techniques are unlikely to detect viruses 
with very low loads in cancers as compared to amplification 
techniques such as PCR (36).
Despite these differences, the outcome of the PCR-based case–
control studies is consistent despite having been conducted with 
different techniques, locations, and times by different research 
groups (Table  2). As stated above, the prevalence of high-risk 
HPVs in breast cancers is fourfold higher than in normal and 
benign breast controls. This is a substantial difference between 
benign breast and breast cancers and cannot be attributed to dif-
ferences in laboratory techniques.
TABLe 2 | identification of high-risk HPvs in breast cancer and benign or normal breast controls in case–control studies.
Reference Country HPv-positive breast  
cancers/total breast cancers
HPv-positive non-cancer breast/total  
non-cancer breast controls
Main HPv types
Yu et al. (8) Japan/China 18/52 (35%) 0/15 (0%) 18, 33
Damin et al. (11) Brazil 25/101 (25%) 0/41 (0%) 16, 18
Tsai et al. (12) Taiwan 8/62 (13%) 2/42 (5%) Not available
Choi et al. (13) Korea 8/123 (7%) 0/31 (0%) 16, 18, 58
Gumus et al. (14) Turkey 37/50 (74%) 9/16 (56%) 18, 33
He et al. (15) China 24/40 (60%) 1/20 (5%) 16
de Leon et al. (16) Mexico 15/41 (37%) 0/43 (0%) 16, 18
Heng et al. (17) Australia 8/26 (31%) 3/28 (11%) 16, 18
Herrera-Romano et al. (5) Mexico 6/60 (10%) 7/60 (12%) 16
Mou et al. (18) China 4/62 (6%) 0/46 (0%) 16, 18
Chang et al. (19) China 0/48 (0%) 3/30 (10%) 6, 11
Sigaroodi et al. (20) Iran 15/43 (35%) 1/40 (3%) 16, 18
Frega et al. (21) Italy 9/31 (29%) 0/12 (0%) 16, 18
Glenn et al. (22) Australia 25/50 (50%) 8/40 (20%) 16, 18
Liang et al. (23) China 48/224 (21%) 6/37 (16%) 16, 18, 33, 58
Ahangar-Oskouee et al. (24) Iran 22/65 (34%) 0/65 (0%) 16
Ali et al. (25) Iraq 60/129 (47%) 3/41 (7%) 16, 18, 33
Eslamifar et al. (26) Iran 0/100 (0%) 0/50 (0%)
Manzouri et al. (27) Iran 10/55 (18%) 7/51 (14%) 16
Peng et al. (28) China 2/100 (2%) 0/50 (0%) 18
Fu et al. (9) China 25/169 (15%) 1/83 (1%) 58
Li et al. (29) China 3/187 (2%) 0/92 (0%) 6, 16, 18
Zhou et al. (6) China 0/77 (0%) 0/77 (0%)
Vernet-Tomas et al. (30) Spain 0/76 (0%) 0/2 (0%)
These data indicate that high-risk HPVs are fourfold more prevalent in breast tumors as compared to non-cancer controls. This parallels the findings of a recent meta-analysis based 
on selected studies included in this Table (7).
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epidemiology
If HPV infections were major contributors to breast cancer, 
it would be anticipated that countries with high rates of HPV 
associated cervical cancer would also have high rates of HPV 
associated breast cancer. The opposite appears likely, namely that 
countries with low rates of cervical cancer appear to have high 
rates of breast cancer (37). This is shown in Table 3. While these 
data must be considered only as broad trends, the implication is 
that HPVs are unlikely to be major contributors to breast cancer. 
However, it remains possible that HPVs may be involved in some 
but not all breast cancers.
Epidemiological combined with experimental data have dem-
onstrated that (i) the prevalence of high-risk HPVs is high in early 
as compared to late breast cancer, (ii) this early influence of HPVs 
is indirect and operates by the destabilizing effects of HPV on 
the human genome via APOBEC3B enzyme (38). This influence 
of HPV on APOBEC enzymes has been confirmed (39). It has 
also been demonstrated that high expression of HPV E7 protein 
in benign breast tissues as compared to low HPV E7 expression 
in subsequent HPV positive breast cancer occurs in the same 
patients (40). This is additional evidence that the influence of 
HPVs occurs early in breast cancer.
This indirect influence of HPVs in breast cancer needs to be 
considered in the context of the epidemiological observations by 
Grulich and Vajdic (41) that the prevalence of breast cancer is not 
increased in immunocompromised patients (patients with HIV 
infections or organ transplant recipients). This compares to the 
fourfold to sixfold increase in cervical cancer in these patients. 
Again the implication is that the influences of HPV are indirect 
and occur early in breast oncogenesis.
There is also evidence that HPVs may collaborate with 
EBV and which together may have oncogenic influences. The 
co-prevalence of HPVs and EBV in nasopharyngeal and breast 
cancers has been demonstrated (22, 42, 43).
Specificity
Specificity is a very weak causative criterion in both communica-
ble and non-communicable diseases and probably should not be 
included in the Hill list of causal criteria. Any associations between 
HPVs and breast cancer are obviously not specific. HPV is well 
established as a causal factor in other cancers such as cervical and 
head and neck cancers. In addition, high-risk HPVs have been 
identified in a wide range of other cancers and non-cancerous 
tissues (44). In the past, HPVs have been regarded as being spe-
cific to epithelial cells including breast epithelial cells. However, 
HPV gene sequences have been identified in non-epithelial cell 
brain tumors and in coronary and aorta artery smooth muscle 
cells (45).
Temporality (Time Sequence)
High-risk HPVs have been identified in benign breast tissues of 
the same type as in breast tumors, which subsequently developed 
in the same patients (10). The identification of HPVs preceded 
TABLe 3 | incidence and mortality per 100,000 women (age adjusted) of 
cervical and breast cancers.
incidence  
cervical  
cancer
incidence  
breast  
cancer
Mortality  
cervical  
cancer
Mortality  
breast  
cancer
France 8 92 2 17
England 7 90 2 18
United States 5 84 4 14
Australia 5 82 2 14
Canada 5 76 3 15
China 6 44 5 5
India 16 32 10 10
Japan 7 32 4 8
Thailand 23 25 10 10
Selected high and low cervical cancer country data (17).
Low cervical cancer correlates with higher breast cancer incidence and mortality 
(incidence p = 0.052, mortality p = 0.118). As HPV is almost universally associated 
with cervical cancer, these data suggest that HPV is not a major cause of breast 
cancer. These data demonstrate trends only. Incidence is influenced by screening, and 
mortality is influenced by accuracy of diagnosis and effectiveness of treatment.
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the development of breast cancer in the same patients by between 
1 and 11 years. As this study was retrospective, the time of the 
original HPV infection cannot be determined. Similarly, HPV-
associated cervical infections and abnormal cervical pathology 
can precede the development of same type HPV positive breast 
cancer in the same patient (38, 46). Again, however, the time of 
the original HPV infection cannot be determined.
These observations confirm that the HPV infections precede 
the development of HPV-positive breast cancer.
Biological Gradient, Plausibility,  
and Coherence
These criteria overlap. The biological gradient or response differs 
greatly with respect to the HPV viral load in breast as compared to 
cervical cancer. The HPV viral load in breast cancer is 2,000-fold 
less than in cervical cancer, as shown in Table 1. This viral load 
is so low that any direct HPV oncogenic influence is likely to be 
small. It is possible that HPV oncogenic influences in breast cancer 
are indirect. This is because there is no increase in the prevalence 
of breast cancer in patients with induced immunosuppression or 
with immunity suppressed by human immunodeficiency virus 
(HIV) (41). This is in contrast to the up to sixfold increase in 
prevalence of HPV associated cervical cancer in similar patients. 
Transcription from HPV DNA to RNA in HPV-associated 
breast cancer has not been identified by some investigators (47). 
However, a very low prevalence of HPV transcripts has been 
identified in the TCGA series of breast tumors (10). An indication 
of some HPV viral transcription in some breast cancers is the 
identification of HPV E7 protein expression (10).
The oncogenic capacity of high-risk HPVs is well established 
(3). Accordingly, it is plausible that high-risk HPVs could have 
a role in breast cancer. The transmission of HPVs during sexual 
activities involving surface to surface contact between epithelial 
cells is also well documented (48). Not so well known is the iden-
tification of high-risk HPVs in white blood cells, which suggests 
a means of HPV transmission throughout the body (49).
Band et  al. have repeatedly demonstrated that HPV DNAs 
can immortalize normal human mammary epithelial cells in 
experimental conditions (50, 51). This evidence demonstrates 
that HPVs have the capacity to have a causal role in breast cancer. 
However, it is not conclusive evidence of causality because the 
influence of HPVs and their oncogenic proteins may differ in 
experimental conditions than in normal women.
Mechanisms of Oncogenesis
The oncogenic mechanisms by which HPV induces cervical 
cancer have been intensively studied (3). High-risk HPV encodes 
a series of proteins, designated as early (E1–E7) or late (L1 and 
L2). Although all of the viral proteins have a role in viral replica-
tion, only a small number of the viral early proteins have a role 
in cellular transformation. Transformation is due to the HPV E6 
and E7 oncoproteins, which work in concert to disrupt cell-cycle 
regulation, inhibit apoptosis, and stimulate cell cycle progression 
by binding/inhibiting the p53 and p110RB tumor suppressor 
genes, respectively.
p53 protein expression has been shown to be significantly 
inhibited in HPV-positive breast cancer as compared to HPV-
negative breast cancer (46). This indicates that HPVs in breast 
cancer may be biologically active.
In addition, HPV E5 and E6 act early in transformation 
(before integration) and can disrupt cytokeratin causing 
perinuclear cytoplasmic clearing and nuclear enlargement, 
which leads to the appearance of a koilocyte (52). Koilocytes 
are shown in Figure  1. HPV associated koilocytes have been 
identified in breast tumors, which is an indication of early influ-
ences of HPVs on normal breast epithelial cells (53). Oncogenic 
protein HPV E7 expression has been observed in both benign 
and subsequent breast cancers in the same patients (10). This 
is an indication of HPV oncogenic activity. HPV type 16 E6 
and E7 oncoproteins have been shown to convert non-invasive 
breast cancer cells into an invasive form both in vitro and in 
nude mice (54).
HPV E7 is more frequently expressed in benign breast biopsy 
specimens than in subsequent breast cancers that developed 
several years after the biopsy (40). This is shown in Figure 1. This 
suggests that HPVs may have an early role in breast cancer – the 
“hit and run” phenomenon. These direct influences are probably 
limited because, as indicated above, there is no increase in the 
prevalence of breast cancer in immunocompromised patients 
(41). If HPVs had a major direct influence in breast cancer, it 
would be anticipated that the prevalence would be increased in 
these patients.
Recent evidence suggests that high-risk HPVs may have 
an indirect oncogenic influence in the development of breast 
cancer. HPVs can promote the activity or influences of a DNA-
editing enzyme APOBEC3B, which is a protein encoded by the 
APOBEC3B gene (38, 39). Upregulated APOBEC3B protein 
expression was first identified by Burns et  al. as an enzymatic 
source of mutations in breast cancer (55). Upregulation of 
APOBEC3B can occur in many different cancers (55). It has also 
been shown that high expression of APOBEC3B can be associ-
ated with aggressive breast cancers (56).
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Finally, HPVs may collaborate with other oncogenic viruses 
such as EBV to cause breast cancer. The evidence for such a col-
laboration is very limited and mainly consists as an association 
(22, 43, 57). There is unpublished experimental evidence, which 
supports this notion (58).
DiSCUSSiOn AnD COnCLUSiOn
The fourfold higher prevalence of high-risk HPVs in breast cancer 
as compared to normal and benign breast tissues is a consistent 
finding among over 25 studies conducted in different laboratories 
in many contrasting populations. This phenomenon is strongly 
suggestive of a role of high-risk HPVs in breast cancer. However, 
the nature of this role is far from clear. HPVs do not appear to have 
a direct oncogenic influence in breast cancer as demonstrated by 
the fact that the prevalence of breast cancer is not increased in 
immunocompromised patients (as compared to the fourfold to 
sixfold increase in cervical cancer in these patients). HPV E7 
oncprotein is highly expressed in benign breast tissues but lowly 
expressed in breast cancer tissues in the same patients. This is an 
indication of early HPV influences. The implication is that the 
influences of HPV in breast cancer are probably early and indirect 
and without major influences of the immune system.
It can be argued that ubiquitous infections such as with 
HPVs cannot be associated with cancer. However, this is not a 
correct argument as shown by the example of EBV. Over 90% of 
Western populations become infected to EBV at some time in 
their lives. Rarely, these ubiquitous EBV infections cause serious 
cancers such as Burkitt’s lymphoma, nasopharyngeal cancer, and 
lymphomas. Interestingly, EBV infections that lead to cancer 
frequently do so in collaboration with other infectious agents, 
such as malaria, in the case of Burkitt’s lymphoma and HPVs in 
the case of nasopharyngeal cancers.
With the exception of the unimportant criteria of specificity, 
all the criteria for a causal role for high-risk HPVs in breast 
cancer have been met. High-risk HPVs have a well-documented 
oncogenic capacity (3). HPVs have been consistently identified 
in breast cancers by different workers in different laboratories 
in a wide range of countries (7). The odds ratio of HPV positive 
breast cancers is high as compared to benign breast biopsy and 
normal breast controls (7). There is evidence of HPV breast 
infection prior to the development of HPV positive breast can-
cer (10, 31, 38). HPV-associated cervical pathology can precede 
same HPV type positive breast cancer, and women with cervi-
cal pathology are at greater than expected risk of developing 
breast cancer (31, 46). There are plausible mechanisms, which 
indicate that HPVs may have an oncogenic influence on the 
breast (38).
However, the extremely low HPV viral load in breast cancers 
and the unchanged prevalence of breast cancer in immunocom-
promised women indicate a need for cautious conclusions.
Also, because multiple viruses (mouse mammary tumor virus, 
EBV, and bovine leukemia virus) may have roles in human breast 
cancer, it will be difficult to identify the influence of a vaccine 
aimed at a single virus. On the other hand, given the strong 
possibility that high-risk HPVs do have a role in some breast 
cancers, it is reasonable to promote the use of HPV vaccines, 
such as Gardasil, as they are very effective in reducing the risk of 
cervical cancer.
Based on this evidence, high-risk HPVs may have a causal role 
in a subset of breast cancers.
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